MFG-IRAP University of Pittsburgh

Current Opinion in Investigational Drugs

Volumn 1, Issue 2, 2000, Pages 194-198

  Baragi, V M ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 1 RECEPTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA;

CARTILAGE DEGENERATION; CLINICAL TRIAL; DNA TRANSFECTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; EDEMA; FEMALE; GENE THERAPY; HUMAN; INFLAMMATION; NONHUMAN; OSTEOARTHRITIS; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; RETROVIRUS; REVIEW; RHEUMATOID ARTHRITIS; SKIN ALLERGY; SYNOVIUM; TREATMENT OUTCOME;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS; CELL TRANSPLANTATION; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; GENE THERAPY; HUMANS; RETROVIRIDAE;

EID: 0033752262     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Gene therapy for inflammation?
2. Gene therapy
3. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis
4. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy
5. Prolonged systemic expression of human IL-1 receptor antagonist (hIL-1ra) in mice reconstituted with hematopoietic cells transduced with a retrovirus carrying the hIL-1ra cDNA
6. Intra-articular expression of bologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer
7. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group
8. Pathway to gene therapy in rheumatoid arthritis
9. Suppression of experimental arthritis by gene transfer of interleukin-1 receptor antagonist cDNA
10. Direct gene delivery to synovium: An evaluation of potential vectors in vitro and in vivo
11. University of Pittsburgh Medical Center researchers present preliminary evidence demonstrating gene expression in world's first arthritis gene therapy patient
12. Inhibition of interleukin-1-induced effects in synoviocytes transduced with the human IL-1 receptor antagonist cDNA using an adenoviral vector
13. Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective
14. Constitutive systemic expression of IL-1Ra or soluble TNF receptor by genetically modified hematopoietic cells suppresses LPS induction of IL-6 and IL-10
15. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy
16. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee
17. Transplantation of transduced chondrocytes protects articular cartilage from interleukin 1-induced extracellular matrix degradation
18. Bilogic basis for interleukin-1 in disease
19. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interluekin-1 receptor antagonist in healthy humans
20. Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: Implications for arthritis gene therapy
21. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
22. Inflammation - Fourth Workd Congress (Part II), Paris, France
23. Clinical gene therapy for arthritis